BioSpace News Archive

As part of the Trump Administration’s all-hands-on-deck approach across public, academic and private sectors to combat the COVID-19 pandemic, the U.S. Food and Drug Administration stood up a new program to expedite the development of potentially safe and effective life-saving treatments.

Innoviva, Inc. announced that, due to the public health impact of the coronavirus pandemic, the location of the Company’s 2020 annual meeting of stockholders has been changed and will be held in a virtual meeting format only.

AVEO Oncology announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor, as a treatment for relapsed or refractory renal cell carcinoma.

3M Chairman and CEO Mike Roman issued the following update announcing additional details about 3M’s capacity increases of N95 respirators, strong measures to combat price gouging and counterfeiting, and new partnerships to help protect our healthcare workers on the front lines:

Select Medical Holdings Corporation, announced a change in the location of the Company’s 2020 Annual Meeting of Stockholders.

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced a grant of inducement awards to its Chief Legal and Business Officer, Jason A. Okazaki on March 26, 2020.

American Association of Nurse Anesthetists —The Centers for Medicare & Medicaid Services has temporarily suspended physician supervision requirements for Certified Registered Nurse Anesthetists —an action that the American Association of Nurse Anesthetists deems a critical step for CRNAs to serve the U.S. healthcare system more effectively during the COVID-19 pandemic.

Amid the uncertainty surrounding the COVID-19 pandemic, Children’s Minnesota and its patients have joined the “A World of Hearts” movement to inspire hope.

Prothena Corporation plc announced that baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease will be presented by Roche in an oral presentation at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD Focus Meeting, to be held virtually on April 2-5, 2020.

Orchard Therapeutics, a global leader in gene therapy, provided an update on its business and operations, outlining how the COVID-19 pandemic has and may continue to impact the company’s development programs and timelines, product supply, commercial operations and financial position.